(AOF) – Genomic Vision had cash of 14,000 euros as of June 30, 2023, compared to 760,000 euros as of June 30, 2022, and the financial resources available in the short term should only allow it to finance its activities “until end of October 2023.” The company, which develops tools and services dedicated to the analysis and control of genome modifications, is “actively working on several financing and operational structuring options in order to quickly secure the additional financial resources necessary for its continued development.”
The half-year net loss reached 6.4 million euros, compared to 2.56 million a year ago, for a turnover increased from 511,000 to 593,000 euros.
Genomic Vision “anticipates a gradual extension of its financing horizon to 12 months, in several stages”: it first envisages “the realization in the very short term of operations on which it is actively working and which should enable it to strengthen its own funds and thus continue its activities over the financial year. Other complementary initiatives would then allow it to extend its financial horizon “at least until the end of 2024”. On the basis of these elements, “the hypothesis of continuity of operation was retained by the management of the company” even if it is not guaranteed that the anticipated financing will be available.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
